The glucose transporter type 1 (Glut1) syndromes

Area of Science:

• Neuroscience
• Genetics
• Metabolic Disorders

Background:

• Glucose transporter type 1 (Glut1) is crucial for brain energy supply via the blood-brain barrier.
• Glut1 deficiency syndrome (Glut1-DS), first described in the early 1990s, causes infantile seizures, developmental delay, microcephaly, and ataxia.
• Recent findings reveal milder Glut1 deficiency variants and expand understanding of its pathophysiology.

Purpose of the Study:

• To summarize the clinical manifestations of Glut1 syndromes.
• To discuss the genetic mutations underlying Glut1 deficiency.
• To explore genotype-phenotype correlations and functional test data.

Main Methods:

• Review of clinical features associated with Glut1 defects.
• Analysis of genetic mutations causing Glut1 deficiency.
• Examination of functional tests and genotype-phenotype correlations.

Main Results:

• Glut1 defects can manifest as various epilepsy types (EOAE, CAE, MAE) and movement disorders (PED, CSE).
• Milder variants of Glut1-DS have been identified.
• Ketogenic diet therapy shows significant efficacy, especially when initiated early.

Conclusions:

• Glut1 syndromes encompass a spectrum of neurological disorders with diverse clinical presentations.
• Understanding genetic mutations and their functional impact is key to diagnosing and managing Glut1-DS.
• Early intervention with a ketogenic diet offers a highly effective treatment for improving outcomes in Glut1 deficiency syndromes.